Loading...
Market
Which biotech company will Takeda invest in by June 30, 2025?
3
Resolution / Starting Odds
Wave Life Sciences • 25%
CRISPR Therapeutics • 25%
Moderna • 25%
Other • 25%
Official announcements from Takeda Pharmaceutical Company
Story
Takeda Ends Six-Year $260M Collaboration with Wave Life Sciences on Mutant Huntingtin-Specific ASO
Oct 16, 2024, 08:55 AM
Takeda Pharmaceutical Company, a Japanese pharma, has decided to terminate its option for the mutant huntingtin-specific ASO target in its collaboration with Wave Life Sciences. This decision marks the end of a six-year partnership into which Takeda had invested $260 million. The collaboration was focused on developing treatments for Huntington's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Wave Life Sciences • 25%
ProQR Therapeutics • 25%
Korro Bio • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Johnson & Johnson • 25%
Merck • 25%
AstraZeneca • 25%
Other • 25%